Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price fell 7.4% on Friday . The company traded as low as C$0.23 and last traded at C$0.25. 287,012 shares were traded during mid-day trading, an increase of 141% from the average session volume of 119,241 shares. The stock had previously closed at C$0.27.
Theralase Technologies Price Performance
The stock has a fifty day moving average of C$0.27 and a two-hundred day moving average of C$0.21. The stock has a market cap of C$61.39 million, a price-to-earnings ratio of -12.50 and a beta of 1.36. The company has a quick ratio of 3.40, a current ratio of 1.21 and a debt-to-equity ratio of 20.58.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Stories
- Five stocks we like better than Theralase Technologies
- What is a Death Cross in Stocks?
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Differences Between Momentum Investing and Long Term Investing
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is the Shanghai Stock Exchange Composite Index?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
